(vianews) - sanofi (san.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| sanofi (san.pa) | €90.96 | 3.75% | 5.82% |
| equasens (eqs.pa) | €51.30 | 2.31% | 20.83% |
| ipsen (ipn.pa) | €110.30 | 1.04% | 17.91% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. sanofi (san.pa)
3.75% forward dividend yield and 5.82% return on equity
sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the united states, europe, canada, and internationally. it operates through pharmaceuticals, vaccines, and consumer healthcare segments. the company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. in addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis a, typhoid, cholera, yellow fever, and rabies vaccines. the company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. further, it has a collaboration and license agreement with exscientia to develop up to 15 novel small-molecule for oncology and immunology; abl bio, inc. to develop abl301, a treatment for alpha-synucleinopathies; blackstone life sciences to develop pivotal studies and clinical development program; and seagen inc. to design, develop, and commercialize antibody-drug conjugates for cancer. additionally, the company has a collaboration agreement with igm biosciences, inc. to develop, manufacture, and commercialize igm antibody; skyhawk therapeutics, inc to discover and develop novel small molecules; and adagene inc., for the discovery and development of antibody-based therapies. it also has collaborations with scribe therapeutics inc. to develop genome editing technologies; and co-promotion service agreement with provention bio, inc. for the commercialization of teplizumab. the company was formerly known as sanofi-aventis and changed its name to sanofi in may 2011. sanofi was incorporated in 1994 and is headquartered in paris, france.
earnings per share
as for profitability, sanofi has a trailing twelve months eps of €4.3.
pe ratio
sanofi has a trailing twelve months price to earnings ratio of 21.15. meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.82%.
revenue growth
year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08b for the twelve trailing months.
more news about sanofi.
2. equasens (eqs.pa)
2.31% forward dividend yield and 20.83% return on equity
equasens société anonyme provides healthcare it solutions in europe. it offers id. patient, a business software; id. mobility, a back-office management software; pandalab pro, an instant messaging solution; id. vente, an has-certified drug database; id. commande, an order management module; dispensing robots; services ségur id; id. dosage, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; visiodroits module; and website connector. the company also provides id. desk, an informative and interactive dashboard; id. up!, a real-time monitoring and control application of id management software; id. easyq, a queue management solution; miaterapia; id. show, an application for managing real-time communications on pharmacy screens; pharmaweb; tsgatepro; lmo, a dispensary business software; and lgo, a dispensary management software. in addition, it offers domilink had software; mobisoins mobility tool; memorialis, support software for alzheimer's monitoring teams; hospilink, an hospital information system applications; hospilink dpi, a computerized patient file; hospilink lookup big data; enephro solutions; noviacare solutions; kap&link2, a contact chip card reader terminal and nfc reader; es-kap-ad, a connected nomadic tool incorporating software; kap-inside, a mobile terminal; and ti-kap allowing access to contact and contactless cards. further, the company provides authenticator, a patented authentication system; kap'teur by kapelse, a patented universal sensor; expressvitale; médistory, that automates the transfer of invoicing to the healthcare professional's accounting. additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. the company was incorporated in 1996 and is headquartered in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.
earnings per share
as for profitability, equasens has a trailing twelve months eps of €3.2.
pe ratio
equasens has a trailing twelve months price to earnings ratio of 16.03. meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.83%.
volume
today's last reported volume for equasens is 9273 which is 12.45% below its average volume of 10592.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, equasens's stock is considered to be overbought (>=80).
more news about equasens.
3. ipsen (ipn.pa)
1.04% forward dividend yield and 17.91% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. its product pipeline comprises cabometyx + atezolizumab, which is in phase iii clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and taverik, which is in phase iii for the treatment of second line follicular lymphoma; bylvay, which is in phase iii for the treatment of biliary atresia; dysport, which is in phase iii clinical trial for the treatment of chronic and episodic migraine; fidrisertib, which is in phase ii clinical trial for the treatment of fibrodysplasia ossificans progressiva; elafibranor, which is in phase ii for the treatment of primary sclerosing cholangitis, as well as ipn60250; ipn10200, which is in phase ii for the treatment of longer-acting neurotoxin aesthetics and therapeutics; ipn60210, which is in phase i clinical trial for the treatment of relapsed/refractory multiple myeloma; and ipn60260 for the treatment of viral cholestatic disease and is in phase i clinical trial. the company also offers somatuline, decapeptyl, cabometyx, onivyde, tazverik, and other oncology products; dysport and other neurosciences products; and bylvay, nutropinaq, increlex, and sohonos for rare diseases. the company was founded in 1929 and is based in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €7.4.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 14.91. meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.91%.
volatility
ipsen's last week, last month's, and last quarter's current intraday variation average was 0.18%, 0.21%, and 1.11%.
ipsen's highest amplitude of average volatility was 0.48% (last week), 0.95% (last month), and 1.11% (last quarter).
volume
today's last reported volume for ipsen is 106351 which is 33.58% above its average volume of 79614.
revenue growth
year-on-year quarterly revenue growth grew by 7.9%, now sitting on 3.44b for the twelve trailing months.
dividend yield
as stated by morningstar, inc., the next dividend payment is on may 30, 2024, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 1.04%.
more news about ipsen.